Galectin Therapeutics Inc (GALT) stock
GALTNasdaqPharmaceutical PreparationsFiscal year ends December 31
$2.98+0.07 (+2.41%)
Close on Nov 18, 2026Market cap $300.53MP/E –Yield –
Galectin Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Galectin Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$15.62M. For fiscal 2025 it was -$20.09M. The highest annual figure on record is -$4.88M in fiscal 2010.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$20.09M | – |
| FY2024 | Dec 31, 2024 | -$42.43M | – |
| FY2023 | Dec 31, 2023 | -$38.07M | – |
| FY2022 | Dec 31, 2022 | -$38.35M | – |
| FY2021 | Dec 31, 2021 | -$30.18M | – |
| FY2020 | Dec 31, 2020 | -$23.44M | – |
| FY2019 | Dec 31, 2019 | -$13.44M | – |
| FY2018 | Dec 31, 2018 | -$13.60M | – |
| FY2017 | Dec 31, 2017 | -$16.25M | – |
| FY2016 | Dec 31, 2016 | -$21.48M | – |
| FY2015 | Dec 31, 2015 | -$20.08M | – |
| FY2014 | Dec 31, 2014 | -$15.43M | – |
| FY2013 | Dec 31, 2013 | -$12.10M | – |
| FY2012 | Dec 31, 2012 | -$9.90M | – |
| FY2011 | Dec 31, 2011 | -$10.41M | – |
| FY2010 | Dec 31, 2010 | -$4.88M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$3.98M | – |
| Q1 FY2026 | Mar 31, 2026 | -$4.08M | – |
| Q4 FY2025 | Dec 31, 2025 | -$3.37M | – |
| Q3 FY2025 | Sep 30, 2025 | -$4.20M | – |
| Q2 FY2025 | Jun 30, 2025 | -$4.63M | – |
| Q1 FY2025 | Mar 31, 2025 | -$7.90M | – |
| Q4 FY2024 | Dec 31, 2024 | -$12.43M | – |
| Q3 FY2024 | Sep 30, 2024 | -$9.07M | – |
| Q2 FY2024 | Jun 30, 2024 | -$11.29M | – |
| Q1 FY2024 | Mar 31, 2024 | -$9.65M | – |
| Q4 FY2023 | Dec 31, 2023 | -$9.56M | – |
| Q3 FY2023 | Sep 30, 2023 | -$9.17M | – |
| Q2 FY2023 | Jun 30, 2023 | -$9.00M | – |
| Q1 FY2023 | Mar 31, 2023 | -$10.34M | – |
| Q4 FY2022 | Dec 31, 2022 | -$10.63M | – |
| Q3 FY2022 | Sep 30, 2022 | -$8.12M | – |
| Q2 FY2022 | Jun 30, 2022 | -$9.66M | – |
| Q1 FY2022 | Mar 31, 2022 | -$9.94M | – |
| Q4 FY2021 | Dec 31, 2021 | -$7.43M | – |
| Q3 FY2021 | Sep 30, 2021 | -$8.24M | – |
| Q2 FY2021 | Jun 30, 2021 | -$8.19M | – |
| Q1 FY2021 | Mar 31, 2021 | -$6.32M | – |
| Q4 FY2020 | Dec 31, 2020 | -$7.83M | – |
| Q3 FY2020 | Sep 30, 2020 | -$5.93M | – |
| Q2 FY2020 | Jun 30, 2020 | -$6.10M | – |
| Q1 FY2020 | Mar 31, 2020 | -$3.58M | – |
| Q4 FY2019 | Dec 31, 2019 | -$5.19M | – |
| Q3 FY2019 | Sep 30, 2019 | -$2.86M | – |
| Q2 FY2019 | Jun 30, 2019 | -$3.02M | – |
| Q1 FY2019 | Mar 31, 2019 | -$2.37M | – |
| Q4 FY2018 | Dec 31, 2018 | -$2.99M | – |
| Q3 FY2018 | Sep 30, 2018 | -$2.68M | – |
| Q2 FY2018 | Jun 30, 2018 | -$3.76M | – |
| Q1 FY2018 | Mar 31, 2018 | -$4.18M | – |
| Q4 FY2017 | Dec 31, 2017 | -$2.37M | – |
| Q3 FY2017 | Sep 30, 2017 | -$4.41M | – |
| Q2 FY2017 | Jun 30, 2017 | -$4.51M | – |
| Q1 FY2017 | Mar 31, 2017 | -$4.95M | – |
| Q4 FY2016 | Dec 31, 2016 | -$4.60M | – |
| Q3 FY2016 | Sep 30, 2016 | -$4.54M | – |
See a number that looks wrong?